![FENC - Fennec Pharmaceuticals Inc - Stock Price Chart]() |
Market Cap | 242.50M | EPS (ttm) | -0.51 |
P/E | - | EPS this Y | - |
Forward P/E | 9.91 | EPS next Y | 392.22% |
PEG | - | EPS past 5Y | 52.21% |
P/S | 7.85 | EPS next 5Y | - |
P/B | - | EPS Q/Q | -110.22% |
Dividend | - | Sales Q/Q | -65.52% |
Insider Own | 16.61% | Inst Own | 57.71% |
Insider Trans | -1.38% | Inst Trans | -3.43% |
Short Float | 5.67% | Earnings | May 13/b |
Analyst Recom | 1.00 | Target Price | 13.80 |
Avg Volume | 81.55K | 52W Range | 3.96 - 9.11 |
|
|
|
Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
RALLIS CHRIS A | Director | Jul 07 '25 | Option Exercise | 2.35 | 2,127 | 4,998 | 55,911 | Jul 07 05:31 PM | RALLIS CHRIS A | Director | Jul 07 '25 | Sale | 8.71 | 1,119 | 9,746 | 54,792 | Jul 07 05:31 PM | Raykov Rosty | Director | Jul 03 '25 | Sale | 8.61 | 10,000 | 86,100 | 60,670 | Jul 07 04:30 PM | ROSTISLAV RAYKOV | Director | Jul 03 '25 | Proposed Sale | 8.61 | 10,000 | 86,102 | | Jul 03 02:01 PM | Raykov Rosty | Director | Jun 05 '25 | Sale | 7.78 | 10,000 | 77,800 | 65,462 | Jun 06 04:20 PM |
|
|
 |
![NVDA - NVIDIA Corp - Stock Price Chart]() |
Market Cap | 4024.05B | EPS (ttm) | 3.10 |
P/E | 53.12 | EPS this Y | 44.57% |
Forward P/E | 28.75 | EPS next Y | 32.68% |
PEG | 1.76 | EPS past 5Y | 91.83% |
P/S | 27.10 | EPS next 5Y | 30.17% |
P/B | 47.97 | EPS Q/Q | 27.60% |
Dividend | 0.02% | Sales Q/Q | 69.18% |
Insider Own | 4.07% | Inst Own | 66.35% |
Insider Trans | -0.51% | Inst Trans | 1.06% |
Short Float | 1.04% | Earnings | May 28/a |
Analyst Recom | 1.37 | Target Price | 174.26 |
Avg Volume | 214.71M | 52W Range | 86.62 - 164.50 |
|
|
Jul-10-25 | Initiated |
Goldman |
Buy |
$185 |
|
|
NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
SEAWELL A BROOKE | Director | Jul 11 '25 | Proposed Sale | 166.28 | 48,112 | 7,999,984 | | Jul 11 04:58 PM | HUANG JEN HSUN | Officer | Jul 11 '25 | Proposed Sale | 166.00 | 75,000 | 12,450,159 | | Jul 11 04:54 PM | HUANG JEN HSUN | President and CEO | Jul 10 '25 | Sale | 163.26 | 75,000 | 12,244,385 | 74,798,225 | Jul 10 07:30 PM | HUANG JEN HSUN | President and CEO | Jul 09 '25 | Sale | 163.11 | 75,000 | 12,233,616 | 74,873,225 | Jul 10 07:30 PM | HUANG JEN HSUN | President and CEO | Jul 08 '25 | Sale | 159.36 | 75,000 | 11,952,013 | 74,948,225 | Jul 10 07:30 PM |
|
|
 |
![NNNN - Anbio Biotechnology - Stock Price Chart]() |
Market Cap | 7.09B | EPS (ttm) | 0.06 |
P/E | 812.87 | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | 800.91 | EPS next 5Y | - |
P/B | 117.02 | EPS Q/Q | -267.38% |
Dividend | - | Sales Q/Q | -36.00% |
Insider Own | 9.57% | Inst Own | 0.15% |
Insider Trans | 0.00% | Inst Trans | 310.54% |
Short Float | 0.54% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 95.14K | 52W Range | 5.18 - 52.62 |
|
|
|
Anbio Biotechnology is a medical device company. It is focused on developing and manufacturing a range of in-vitro diagnostic (IVD) products. The company was founded on July 27, 2021 and is headquartered in Frankfurt, Germany. |
|
|  |
![SPPP - Sprott Physical Platinum and Palladium Trust - Stock Price Chart]() |
Market Cap | - | EPS (ttm) | - |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | - | EPS Q/Q | - |
Dividend | - | Sales Q/Q | - |
Insider Own | - | Inst Own | - |
Insider Trans | - | Inst Trans | - |
Short Float | - | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 747.40K | 52W Range | 8.69 - 12.46 |
|
|
|
Sprott Physical Platinum and Palladium Trust is an exchange traded commodity launched and managed by Sprott Asset Management, LP. The fund invests in commodity markets. It invests in physical platinum and palladium bullion in Good Delivery plate or ingot form. Sprott Physical Platinum and Palladium Trust was formed on December 23, 2011 and is domiciled in Canada. |
|
 |
![COIN - Coinbase Global Inc - Stock Price Chart]() |
Market Cap | 98.59B | EPS (ttm) | 5.34 |
P/E | 72.53 | EPS this Y | -45.39% |
Forward P/E | 50.46 | EPS next Y | 48.17% |
PEG | - | EPS past 5Y | - |
P/S | 14.26 | EPS next 5Y | -1.84% |
P/B | 9.41 | EPS Q/Q | -94.50% |
Dividend | - | Sales Q/Q | -13.50% |
Insider Own | 20.70% | Inst Own | 46.47% |
Insider Trans | -1.95% | Inst Trans | -0.01% |
Short Float | 6.94% | Earnings | Jul 31/a |
Analyst Recom | 2.30 | Target Price | 306.53 |
Avg Volume | 13.04M | 52W Range | 142.58 - 389.16 |
|
|
Jul-10-25 | Downgrade |
H.C. Wainwright |
Buy → Sell |
$300 |
|
Today 09:55AM
|
Crypto Currents: Strategy reports Q2 $14.05B unrealized gain on digital assets
(TipRanks) |
Jul-11-25 05:24PM
|
JPMorgan Tells Fintechs to Pay Up for Customer Data Access
(Bloomberg) |
05:08PM
|
Stocks to Watch Recap: Kraft Heinz, Levi Strauss, AMC, Intel
(The Wall Street Journal) |
04:27PM
|
Stock Market Today: Stocks Finish In The Red; Dow Jones Index Bears The Brunt Of Selling
(Investor's Business Daily) |
04:24PM
|
These Stocks Moved the Most Today: Nvidia, MicroStrategy, Boeing, Levi Strauss, AMC, United, Red Cat, and More
(Barrons.com) |
03:39PM
|
Stock Market Today: Dow Jones Is A Big Loser, Nasdaq Weakens; Circle Internet Makes This Bold Move (Live Coverage)
(Investor's Business Daily) |
03:14PM
|
Worlds 6 largest stablecoins: Top cryptocurrencies that maintain a stable price
(Bankrate) |
02:19PM
|
These Stocks Are Moving the Most Today: Nvidia, MicroStrategy, Boeing, Levi Strauss, AMC, United, Red Cat, and More
(Barrons.com) |
02:00PM
|
Bitcoin Sets All-Time High At $118,909, Ethereum, XRP Surge 8% Each
(Benzinga) |
12:26PM
|
Stock Market Today: Dow Falls 300 Points On Trump Tariff News; Drone Makers Are Surging, Here's Why (Live Coverage)
(Investor's Business Daily) |
|
Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Brian Armstrong | Officer | Jul 11 '25 | Proposed Sale | 387.06 | 27,751 | 10,741,302 | | Jul 11 04:44 PM | Armstrong Brian | Chairman and CEO | Jul 01 '25 | Sale | 338.29 | 25,000 | 8,457,278 | 526 | Jul 03 01:33 PM | Grewal Paul | Chief Legal Officer | Jul 02 '25 | Option Exercise | 26.26 | 10,000 | 262,600 | 92,328 | Jul 03 01:32 PM | Grewal Paul | Chief Legal Officer | Jul 02 '25 | Sale | 348.64 | 10,000 | 3,486,433 | 82,328 | Jul 03 01:32 PM | Brian Armstrong | Officer | Jul 01 '25 | Proposed Sale | 335.33 | 25,000 | 8,383,250 | | Jul 01 04:53 PM |
|
|
|  |
![TEL - TE Connectivity plc - Stock Price Chart]() |
Market Cap | 52.52B | EPS (ttm) | 4.56 |
P/E | 38.82 | EPS this Y | 9.09% |
Forward P/E | 19.51 | EPS next Y | 10.07% |
PEG | 3.70 | EPS past 5Y | 12.73% |
P/S | 3.28 | EPS next 5Y | 10.48% |
P/B | 4.35 | EPS Q/Q | -97.52% |
Dividend | 1.54% | Sales Q/Q | 4.44% |
Insider Own | 0.17% | Inst Own | 92.58% |
Insider Trans | -30.16% | Inst Trans | -0.92% |
Short Float | 1.62% | Earnings | Jul 23/b |
Analyst Recom | 1.76 | Target Price | 179.69 |
Avg Volume | 1.76M | 52W Range | 116.30 - 175.31 |
|
|
Jul-11-25 | Upgrade |
Citigroup |
Neutral → Buy |
$200 |
|
|
TE Connectivity Plc is a company that engages in the provision of connectivity and sensor solutions for the purpose of distribution of power, signal, and data. It operates under the following segments: Transportation solutions, Industrial solutions, and Communications solutions. The company was founded in 2007 and is headquartered in Galway, Ireland. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Stucki Aaron Kyle | Pres. Transportation Solutions | Jun 26 '25 | Option Exercise | 93.36 | 13,100 | 1,223,016 | 36,757 | Jun 27 10:05 AM | Stucki Aaron Kyle | Pres. Transportation Solutions | Jun 26 '25 | Sale | 170.00 | 13,100 | 2,227,000 | 23,657 | Jun 27 10:05 AM | AARON K STUCKI | Officer | Jun 26 '25 | Proposed Sale | 170.00 | 13,100 | 2,227,000 | | Jun 26 04:55 PM | Kroeger Shadrak W | Pres., Industrial Solutions | Jun 02 '25 | Option Exercise | 80.20 | 25,000 | 2,005,010 | 50,976 | Jun 03 11:04 AM | Kroeger Shadrak W | Pres., Industrial Solutions | Jun 02 '25 | Sale | 159.03 | 25,000 | 3,975,736 | 25,976 | Jun 03 11:04 AM |
|
|
 |
![AMLX - Amylyx Pharmaceuticals Inc - Stock Price Chart]() |
Market Cap | 684.60M | EPS (ttm) | -3.10 |
P/E | - | EPS this Y | 60.08% |
Forward P/E | - | EPS next Y | 19.09% |
PEG | - | EPS past 5Y | -78.71% |
P/S | - | EPS next 5Y | 30.27% |
P/B | 3.40 | EPS Q/Q | 76.07% |
Dividend | - | Sales Q/Q | -100.00% |
Insider Own | 26.74% | Inst Own | 80.20% |
Insider Trans | -0.45% | Inst Trans | 110.11% |
Short Float | 10.14% | Earnings | May 08/b |
Analyst Recom | 1.11 | Target Price | 11.62 |
Avg Volume | 1.35M | 52W Range | 1.76 - 7.61 |
|
|
Jul-10-25 | Resumed |
Goldman |
Buy |
$10 |
|
|
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
FRATES JAMES M | Chief Financial Officer | Mar 31 '25 | Sale | 3.47 | 10,896 | 37,806 | 290,988 | Apr 02 05:22 PM | Bedrosian Camille L | Chief Medical Officer | Mar 31 '25 | Sale | 3.47 | 12,425 | 43,082 | 194,375 | Apr 02 05:14 PM | Mazzariello Gina | Chief Legal Officer | Mar 31 '25 | Sale | 3.48 | 9,192 | 31,954 | 187,969 | Apr 02 05:12 PM | Cohen Joshua B | Co-Chief Executive Officer | Mar 31 '25 | Sale | 3.47 | 21,490 | 74,482 | 3,355,280 | Apr 02 04:57 PM | Klee Justin B. | Co-Chief Executive Officer | Mar 31 '25 | Sale | 3.46 | 21,490 | 74,454 | 3,355,276 | Apr 02 04:52 PM |
|
|
|  |
![ZVRA - Zevra Therapeutics Inc - Stock Price Chart]() |
Market Cap | 685.14M | EPS (ttm) | -1.89 |
P/E | - | EPS this Y | 182.60% |
Forward P/E | 19.97 | EPS next Y | -66.68% |
PEG | - | EPS past 5Y | 29.64% |
P/S | 16.88 | EPS next 5Y | - |
P/B | 16.70 | EPS Q/Q | 85.60% |
Dividend | - | Sales Q/Q | 495.65% |
Insider Own | 1.18% | Inst Own | 65.35% |
Insider Trans | -16.77% | Inst Trans | 6.85% |
Short Float | 9.24% | Earnings | May 13/a |
Analyst Recom | 1.00 | Target Price | 23.86 |
Avg Volume | 702.29K | 52W Range | 5.45 - 12.37 |
|
|
|
Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Thompson Rahsaan | Chief Legal & Compliance | Jun 26 '25 | Sale | 9.21 | 24,000 | 221,004 | 42,666 | Jun 30 05:02 PM | RAHSAAN THOMPSON | Officer | Jun 26 '25 | Proposed Sale | 9.33 | 24,000 | 223,920 | | Jun 26 04:25 PM | Watton Corey Michael | Director | Mar 28 '25 | Buy | 7.84 | 300 | 2,352 | 1,800 | Mar 31 08:05 PM | Bode John B | Director | Mar 19 '25 | Buy | 7.96 | 10,000 | 79,624 | 40,000 | Mar 21 04:06 PM | Sangiovanni Timothy J. | SVP, Finance & Corp Controller | Feb 13 '25 | Sale | 7.86 | 3,000 | 23,588 | 16,341 | Feb 14 05:57 PM |
|
|
 |
![PARR - Par Pacific Holdings Inc - Stock Price Chart]() |
Market Cap | 1.81B | EPS (ttm) | -1.12 |
P/E | - | EPS this Y | 70.92% |
Forward P/E | 13.69 | EPS next Y | 305.03% |
PEG | - | EPS past 5Y | - |
P/S | 0.23 | EPS next 5Y | 89.87% |
P/B | 1.65 | EPS Q/Q | -789.15% |
Dividend | - | Sales Q/Q | -11.90% |
Insider Own | 5.17% | Inst Own | 96.84% |
Insider Trans | 0.00% | Inst Trans | -3.45% |
Short Float | 5.92% | Earnings | May 06/a |
Analyst Recom | 2.12 | Target Price | 27.12 |
Avg Volume | 1.46M | 52W Range | 11.86 - 34.82 |
|
|
|
Par Pacific Holdings, Inc. engages in the operation of energy and infrastructure businesses. It operates through the following segments: Refining, Retail, Logistics, and Other. The Refining segment produces ultra-low sulfur diesel, gasoline, jet fuel, marine fuel, low sulfur fuel oil, and other associated refined products. The Retail segment sells gasoline, diesel, and retail merchandise. The Logistics segment is involved in terminals, pipelines, a single-point mooring, and trucking operations to distribute refined products throughout the islands of Oahu, Maui, Hawaii, Molokai, and Kauai. The company was founded on December 21, 1984 and is headquartered in Houston, TX. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
CHASE ANTHONY R | Former Director | Jan 31 '25 | Proposed Sale | 16.75 | 14,235 | 238,468 | | Jan 31 05:13 PM | Monteleone William | President and CEO | Dec 16 '24 | Option Exercise | 14.60 | 27,740 | 405,004 | 383,881 | Dec 17 04:34 PM | Monteleone William | President and CEO | Dec 16 '24 | Sale | 15.81 | 26,507 | 419,076 | 357,374 | Dec 17 04:34 PM | Monteleone William | Officer | Dec 16 '24 | Proposed Sale | 15.81 | 26,507 | 419,003 | | Dec 16 04:19 PM | PATE WILLIAM | Director | Dec 12 '24 | Option Exercise | 14.60 | 71,918 | 1,050,003 | 592,310 | Dec 13 08:02 PM |
|
|
 |
![ANSS - Ansys Inc - Stock Price Chart]() |
Market Cap | 32.93B | EPS (ttm) | 6.74 |
P/E | 55.60 | EPS this Y | 5.32% |
Forward P/E | 29.35 | EPS next Y | 11.04% |
PEG | 7.95 | EPS past 5Y | 4.51% |
P/S | 12.75 | EPS next 5Y | 6.99% |
P/B | 5.33 | EPS Q/Q | 48.54% |
Dividend | - | Sales Q/Q | 8.21% |
Insider Own | 0.42% | Inst Own | 90.92% |
Insider Trans | -0.11% | Inst Trans | 1.30% |
Short Float | 2.57% | Earnings | Apr 30/a |
Analyst Recom | 3.15 | Target Price | 346.00 |
Avg Volume | 691.63K | 52W Range | 275.06 - 374.78 |
|
|
|
ANSYS, Inc. engages in the development and marketing of engineering simulation software and services. The firm's solutions include automotive, aerospace and defense, construction, energy, materials and chemical processing, autonomous engineering, and electrification. The company was founded by John A. Swanson in 1970 and is headquartered in Canonsburg, PA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Dorchak Glenda | Director | Apr 14 '25 | Sale | 300.01 | 200 | 60,002 | 3,230 | Apr 15 06:00 PM | GLENDA DORCHAK | Director | Apr 14 '25 | Proposed Sale | 300.01 | 200 | 60,002 | | Apr 14 04:01 PM | Dorchak Glenda | Director | Jan 13 '25 | Sale | 336.62 | 200 | 67,324 | 3,430 | Jan 14 06:00 PM | GLENDA DORCHAK | Director | Jan 13 '25 | Proposed Sale | 336.62 | 200 | 67,324 | | Jan 13 04:07 PM | Dorchak Glenda | Director | Oct 07 '24 | Sale | 313.61 | 152 | 47,669 | 3,630 | Oct 07 06:00 PM |
|
|
|